NCT05309187已完成1 期
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination With Pembrolizumab in Subjects With Advanced, Relapsed, or Refractory Solid Tumors
Immune-Onc Therapeutics19 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2022年4月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 19
- 主要终点
- Incidence of treatment-emergent and serious adverse events in patients treated with IO-202 and IO-202 + pembrolizumab
研究概览
简要总结
To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).
详细描述
This is a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study of IO-202 in adult subjects with advanced relapsed or refractory solid tumors to study safety, tolerability, pharmacokinetic, pharmacodynamics and clinical activity of IO-202 as monotherapy or in combination with pembrolizumab and to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD), and to select the RP2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be ≥18 years old.
- •Part 1 - Dose Escalation: Subject must have any histologically or cytologically confirmed advanced or metastatic solid tumor and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit.
- •Part 2 - Dose Expansion: Subject must have failed at least one available therapy for the disease under study.
- •Subject must have measurable disease per RECIST 1.1 as assessed by local clinical site.
- •Subject must have an Eastern Cooperative Oncology Group performance status of 0 or 1.
排除标准
- •Subject who previously received leukocyte immunoglobulin-like receptor subfamily B (LILRB) or immunoglobulin-like transcript [ILT]) targeting agents including those targeting LILRB1 (ILT2), LILRB2 (ILT4), LILRB4 (ILT3), or leukocyte-associated immunoglobulin-like receptor 1 (LAIR1).
- •Subject who received a biologic systemic anti-cancer therapy <4 weeks or 5 half-lives prior to their first day of study drug administration, or a small molecule systemic anti-cancer therapy or definitive radiotherapy <2 weeks or 5 half-lives prior to their first day of study drug administration or have not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or better from any adverse events (AEs) that were due to prior cancer therapeutics.
- •Subject has symptomatic central nervous system (CNS) tumor.
- •Requires systemic corticosteroids at a dose of >10 mg prednisone or the dose equivalent of other systemic corticosteroid.
- •History of radiation pneumonitis, non-infectious pneumonitis or interstitial lung disease.
- •History of Grade ≥3 immune-related AEs with any prior immunotherapy.
- •Subjects with known hypersensitivity to any of the components of the IO-202 formulation or pembrolizumab.
- •Active known malignancy with the exception of any of the following:
- •Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;
- •Low-risk prostate cancer for which observation or hormonal therapy only is indicated;
- •Any other malignancy treated with curative intent with the last treatment completed ≥ 6 months before study initiation (with the exception of hormonal therapies when indicated).
- •Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) <40% by ECHO or multi-gated acquisition (MUGA) scan ≤28 days prior to Cycle 1 Day 1 (C1D1).
- •Any of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, clinically significant arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch block or controlled atrial fibrillation are allowed.
- •Ongoing cardiac dysrhythmias of Grade 2 or higher per NCI CTCAE, Version 5.
- •Active bacterial, viral, and/or fungal infection including hepatitis B (HBV), hepatitis C, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Subjects with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before study entry.
- •Subject with current active treatment in another interventional therapeutic clinical study.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
结局指标
主要结局
Incidence of treatment-emergent and serious adverse events in patients treated with IO-202 and IO-202 + pembrolizumab
时间窗: From first dose of IO-202 until the end of treatment which is up to 2 years from the first treatment date
safety and tolerability as measured by the incidence of treatment-emergent adverse events.
Dose-limiting toxicities (DLTs) with IO-202 and IO-202 + pembrolizumab
时间窗: From the first dose of IO-202 and IO-202 + pembrolizumab until 21 days after 1st treatment
DLTs as measured by the incidence during Cycle 1.
Study discontinuations due to adverse events (AEs)
时间窗: From the first dose of IO-202 IO-202 and IO-202 + pembrolizumab up to 2 years from the first treatment.
The number of study discontinuations due to AEs
次要结局
- Immunogenicity of IO-202 and IO-202 + pembrolizumab(From the first dose until 24 months after the last treatment)
- Maximum serum concentration (Cmax) of IO-202(From the first dose of IO-202 until Cycle 5, Day 1)
- Minimum concentration of IO-202(From the first dose of IO-202 until the last treatment which is up to 2 years from the first treatment date)
- Anti-tumor activity of IO-202 and IO-202 + pembrolizumab(From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to an estimated period of 24 months)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLAML With Monocytic DifferentiationCMMLNCT04372433Immune-Onc Therapeutics67
招募中
1 期
Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel2024-515674-27-00iOnctura SA16
已完成
1 期
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid TumorsAdvanced Solid TumorNCT05169697Eucure (Beijing) Biopharma Co., Ltd6
终止
1 期
M3541 in Combination With Radiotherapy in Solid TumorsSolid TumorsNCT03225105EMD Serono Research & Development Institute, Inc.15
招募中
1 期
Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaAggressive NK Cell LeukemiaNCT05863234Hiroshima University Hospital7